2025-08-29 - Analysis Report
Okay, here's a report based on the provided data, formatted for clarity and including the requested sections and analysis.

## RXRX Stock Analysis: Recursion Pharmaceuticals Inc.

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -47.26%
*   **VOO Cumulative Return:** 41.70%
*   **Divergence:**
    *   **Current:** -85.4
    *   **Range:** Max: 33.0, Min: -90.3
    *   **Relative Divergence:** 4.0

**Analysis:** RXRX has significantly underperformed the S&P 500. The current divergence of -85.4 indicates a substantial gap in cumulative returns. The relative divergence of 4.0 suggests that RXRX's performance is near the lower end of its historical divergence range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2021-2023  | 5.0%   | 73.6% | -1.0%  | -0.1  | 4.3    |
| 2022-2024  | 0.0%   | 73.6% | -25.0% | 0.1   | 2.9    |
| 2023-2025  | 4.0%   | 73.6% | -50.0% | 0.1   | 2.1    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate fluctuates between 0.0% and 5.0% over the different periods, indicating inconsistent growth.
*   **MDD:** A high Maximum Drawdown of 73.6% across all periods suggests substantial risk and potential for significant losses.
*   **Alpha:** The negative Alpha values, particularly worsening from -1.0% to -50.0%, indicate that RXRX has consistently underperformed relative to its benchmark.
*   **Beta:** A Beta around 0.1 suggests that RXRX has a very low correlation with the market.
*   **Cap:** The market capitalization decreases over time, indicating the stock's contraction.

### 2. Recent Price Action

*   **Current Price:** $4.865
*   **Last Market Change:** Price: $4.865, Previous Close: $4.89, Change: -0.51%
*   **5-Day Moving Average:** $4.871
*   **20-Day Moving Average:** $5.279
*   **60-Day Moving Average:** $5.390

**Analysis:** The stock price is below all three moving averages (5, 20, and 60 days), indicating a short-term downward trend. The slight negative change in the last market suggests continued selling pressure.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.3266 (Low Risk)
*   **RSI:** 37.84
*   **PPO:** -1.28
*   **Hybrid Signal:** cash_70%_Sell (70% of holdings - 3431 shares)
*   **Recent (20-day) Relative Divergence Change:** -1.4 (Negative - Short-term decrease)
*   **Expected Return:** -755.2%

**Analysis:**

*   **MRI:** The MRI suggests a low market risk environment, though this might be specific to the calculation method and should be considered in conjunction with other risk factors.
*   **RSI:** The RSI of 37.84 is approaching oversold territory (below 30), which *could* indicate a potential for a price reversal, but doesn't guarantee it.
*   **PPO:** The negative PPO indicates that the short-term moving average is below the long-term moving average, confirming the bearish trend.
*   **Hybrid Signal:** The hybrid signal strongly recommends selling 70% of holdings and increasing the cash position to 70%, further emphasizing caution, given the MRI of 0.34.
*   **Divergence Change:** The negative change in relative divergence reinforces the short-term downward trend.
*   **Last Market Change:** The recent price fluctuation suggests some volatility. Given the minor change, it reflects normal market activity.
*   **Expected Return:** The extremely negative expected return (-755.2%) indicates a highly unfavorable long-term outlook compared to the S&P 500, suggesting significant underperformance if held for over two years.

### 4. Recent News & Significant Events

*   **2025-08-28:** Major business developments, regulatory changes, or market events are influencing RXRX.
*   **2025-08-26:** Analysts are discussing RXRX's recent performance in the context of industry trends and global economic factors.
*   **2025-08-25:** RXRX's stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **2025-08-29:** Market experts highlight both risks and opportunities for RXRX, advising investors to monitor recent news and company announcements.

**Analysis:** The news suggests significant events impacting RXRX, including volatility, analyst discussions, and regulatory or market changes. Investors should closely monitor these developments.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-08-05 | -0.41 | 0.02 B$ |
| 2025-05-05 | -0.50 | 0.01 B$ |
| 2024-11-06 | -0.34 | 0.03 B$ |
| 2024-08-08 | -0.40 | 0.01 B$ |
| 2025-08-05 | -0.40 | 0.01 B$ |

**Analysis:** RXRX consistently reports negative Earnings Per Share (EPS), indicating ongoing losses. Revenue fluctuates but remains relatively low. This pattern suggests a lack of profitability.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | $0.02B  | -5.54%        |
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |
| 2024-06-30 | $0.01B  | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-06-30 | $0.92B  | -18.70%  |
| 2025-03-31 | $0.93B  | -21.68%  |
| 2024-12-31 | $1.03B  | -17.29%  |
| 2024-09-30 | $0.52B  | -18.27%  |
| 2024-06-30 | $0.58B  | -16.69%  |

**Analysis:**

*   **Revenue and Profitability:** Revenue is inconsistent, and Profit Margins are highly volatile, often deeply negative, indicating significant challenges in achieving profitability.
*   **Capital and Profitability:** Equity fluctuates, and Return on Equity (ROE) is consistently negative, reflecting poor profitability relative to the company's equity.

### 7. Overall Analysis & Conclusion

RXRX is facing significant challenges, reflected in its negative earnings, inconsistent revenue, substantial underperformance compared to the S&P 500, and negative outlook. The technical indicators suggest a downward trend. The hybrid signal strongly recommends selling. The recent news indicates volatility and potential significant events influencing the stock. Investors should exercise extreme caution. The negative EPS and ROE figures, combined with a highly negative expected return, present a concerning financial picture.
